PD-L1, CD47 and now CD24? Star Stanford I/O scientist Irv Weissman points to a ‘major’ new cancer target
Famed Stanford drug researcher Irv Weissman, who helped set off a scramble to develop new drugs that can silence the “don’t eat me” signal sent by CD47, says he and a team of investigators in his lab have found a complementary target on the menu that promises to work where the pioneering drugs fall far short of the mark.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.